Uncoupling of Endothelial Nitric Oxide Synthase in Cardiovascular Disease and its Pharmacological Reversal

Nitric Oxide

Volumn , Issue , 2010, Pages 139-167

  Förstermann, Ulrich ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882544755     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373866-0.00005-8     Document Type: Chapter

References (178)

1. Abu-Soud H.M., Stuehr D.J. Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. Proc. Natl. Acad Sci. U S A 1993, 90:10769-10772.
2. Alderton W.K., Cooper C.E., Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001, 357:593-615.
3. Alheid U., Frölich J.C., Förstermann U. Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. Thromb. Res. 1987, 47:561-571.
4. Arndt H., Smith C.W., Granger D.N. Leukocyte-endothelial cell adhesion in spontaneously hypertensive and normotensive rats. Hypertension 1993, 21:667-673.
5. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 1998, 101:1581-1590.
6. Bachetti T., Comini L., Francolini G., Bastianon D., Valetti B., Cadei M., Grigolato P., Suzuki H., Finazzi D., Albertini A., Curello S., Ferrari R. Arginase pathway in human endothelial cells in pathophysiological conditions. J. Mol. Cell. Cardiol. 2004, 37:515-523.
7. Baek K.J., Thiel B.A., Lucas S., Stuehr D.J. Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. J. Biol. Chem. 1993, 268:21120-21129.
8. Ballinger S.W., Patterson C., Knight-Lozano C.A., Burow D.L., Conklin C.A., Hu Z., Reuf J., Horaist C., Lebovitz R., Hunter G.C., McIntyre K., Runge M.S. Mitochondrial integrity and function in atherogenesis. Circulation 2002, 106:544-549.
9. Barry-Lane P.A., Patterson C., van der Merwe M., Hu Z., Holland S.M., Yeh E.T., Runge M.S. p47phox is required for atherosclerotic lesion progression in ApoE(2/2) mice. J. Clin. Invest. 2001, 108:1513-1522.
10. Bec N., Gorren A.F.C., Mayer B., Schmidt P.P., Andersson K.K., Lange R. The role of tetrahydrobiopterin in the activation of oxygen by nitric-oxide synthase. J. Inorg. Biochem. 2000, 81:207-211.
11. Berkowitz D.E., White R., Li D., Minhas K.M., Cernetich A., Kim S., Burke S., Shoukas A.A., Nyhan D., Champion H.C., Hare J.M. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003, 108:2000-2006.
12. Bivalacqua T.J., Hellstrom W.J., Kadowitz P.J., Champion H.C. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem. Biophys. Res. Commun. 2001, 283:923-927.
13. Blankenberg S., Rupprecht H.J., Bickel C., Torzewski M., Hafner G., Tiret L., Smieja M., Cambien F., Meyer J., Lackner K.J. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl. J. Med. 2003, 349:1605-1613.
14. Böger R.H., Sydow K., Borlak J., Thum T., Lenzen H., Schubert B., Tsikas D., Bode-Böger S.M. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000, 87:99-105.
15. Braunwald E., Domanski M.J., Fowler S.E., Geller N.L., Gersh B.J., Hsia J., Pfeffer M.A., Rice M.M., Rosenberg Y.D., Rouleau J.L. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl. J. Med. 2004, 351:2058-2068.
16. Brunner K., Tortschanoff A., Hemmens B., Andrew P.J., Mayer B., Kungl A.J. Sensitivity of flavin fluorescence dynamics in neuronal nitric oxide synthase to cofactor-induced conformational changes and dimerization. Biochemistry 1998, 37:17545-17553.
17. Buga G.M., Singh R., Pervin S., Rogers N.E., Schmitz D.A., Jenkinson C.P., Cederbaum S.D., Ignarro L.J. Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am. J. Physiol. 1996, 271:H1988-H1998.
18. Busse R., Luckhoff A., Bassenge E. Endothelium-derived relaxant factor inhibits platelet activation. Naunyn Schmiedebergs Arch Pharmacol. 1987, 336:566-571.
19. Butler R., Morris A.D., Belch J.J., Hill A., Struthers A.D. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000, 35:746-751.
20. Cardillo C., Kilcoyne C.M., Cannon R.O., Quyyumi A.A., Panza J.A. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997, 30:57-63.
21. Closs E.I., Scheld J.S., Sharafi M., Forstermann U. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol. Pharmacol. 2000, 57:68-74.
22. Cosentino F., Katusic Z.S. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995, 91:139-144.
23. Cosentino F., Luscher T.F. Tetrahydrobiopterin and endothelial function. Eur Heart J. 1998, 19(Suppl G):G3-G8.
24. Crane B.R., Arvai A.S., Ghosh D.K., Wu C., Getzoff E.D., Stuehr D.J., Tainer J.A. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science 1998, 279:2121-2126.
25. Diet F., Pratt R.E., Berry G.J., Momose N., Gibbons G.H., Dzau V.J. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996, 94:2756-2767.
26. Dikalova A., Clempus R., Lassegue B., Cheng G., McCoy J., Dikalov S., San Martin A., Lyle A., Weber D.S., Weiss D., Taylor W.R., Schmidt H.H., Owens G.K., Lambeth J.D., Griendling K.K. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005, 112:2668-2676.
27. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991, 338:1546-1550.
28. Drummond G.R., Cai H., Davis M.E., Ramasamy S., Harrison D.G. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res. 2000, 86:347-354.
29. Ellis G.R., Anderson R.A., Lang D., Blackman D.J., Morris R.H., Morris-Thurgood J., McDowell I.F., Jackson S.K., Lewis M.J., Frenneaux M.P. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure: effects of short- and long-term vitamin C therapy. J. Am. Coll. Cardiol. 2000, 36:1474-1482.
30. Fleming I., Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284:R1-R12.
31. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5:338-349.
32. Förstermann U., Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113:1708-1714.
33. Förstermann U., Mülsch A., Böhme E., Busse R. Stimulation of soluble guanylate cyclase by an acetylcholine-induced endothelium-derived factor from rabbit and canine arteries. Circ Res. 1986, 58:531-538.
34. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
35. Fukuda Y., Teragawa H., Matsuda K., Yamagata T., Matsuura H., Chayama K. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart 2002, 87:264-269.
36. Fukui T., Ishizaka N., Rajagopalan S., Laursen J.B., Capers Q.t., Taylor W.R., Harrison D.G., de Leon H., Wilcox J.N., Griendling K.K. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res. 1997, 80:45-51.
37. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 1989, 83:1774-1777.
38. Goekjian P.G., Jirousek M.R. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin. Investig. Drugs 2001, 10:2117-2140.
39. Gokce N., Keaney J.F., Frei B., Holbrook M., Olesiak M., Zachariah B.J., Leeuwenburgh C., Heinecke J.W., Vita J.A. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1999, 99:3234-3240.
40. Gorren A.C., Kungl A.J., Schmidt K., Werner E.R., Mayer B. Electrochemistry of pterin cofactors and inhibitors of nitric oxide synthase. Nitric Oxide 2001, 5:176-186.
41. Gorren A.C., List B.M., Schrammel A., Pitters E., Hemmens B., Werner E.R., Schmidt K., Mayer B. Tetrahydrobiopterin-free neuronal nitric oxide synthase: evidence for two identical highly anticooperative pteridine binding sites. Biochemistry 1996, 35:16735-16745.
42. Griendling K.K. Novel NAD(P)H oxidases in the cardiovascular system. Heart 2004, 90:491-493.
43. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000, 86:494-501.
44. Grote K., Flach I., Luchtefeld M., Akin E., Holland S.M., Drexler H., Schieffer B. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ. Res. 2003, 92:e80-e86.
45. Guzik T.J., Mussa S., Gastaldi D., Sadowski J., Ratnatunga C., Pillai R., Channon K.M. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105:1656-1662.
46. Hecker M., Sessa W.C., Harris H.J., Anggard E.E., Vane J.R. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc. Natl. Acad. Sci. U S A 1990, 87:8612-8616.
47. Hein T.W., Zhang C., Wang W., Chang C.I., Thengchaisri N., Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 2003, 17:2328-2330.
48. 2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem. J. 1992, 281(Pt 3):627-630.
49. Heitzer T., Brockhoff C., Mayer B., Warnholtz A., Mollnau H., Henne S., Meinertz T., Munzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase. Circ. Res. 2000, 86:E36-E41.
50. Heitzer T., Krohn K., Albers S., Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000, 43:1435-1438.
51. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673-2678.
52. Heller R., Werner-Felmayer G., Werner E.R. Antioxidants and endothelial nitric oxide synthesis. Eur. J. Clin. Pharmacol. 2006, 62(Suppl 13):21-28.
53. Hemmens B., Mayer B. Enzymology of nitric oxide synthases. Methods Mol. Biol. 1998, 100:1-32.
54. Hemmens B., Goessler W., Schmidt K., Mayer B. Role of bound zinc in dimer stabilization but not enzyme activity of neuronal nitric-oxide synthase. J. Biol. Chem. 2000, 275:35786-35791.
55. Higashi Y., Sasaki S., Nakagawa K., Fukuda Y., Matsuura H., Oshima T., Chayama K. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am. J. Hypertens. 2002, 15:326-332.
56. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., Skatchkov M., Thaiss F., Stahl R.A., Warnholtz A., Meinertz T., Griendling K., Harrison D.G., Förstermann U., Münzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 2001, 88:E14-E22.
57. Hishikawa K., Nakaki T., Suzuki H., Kato R., Saruta T. Role of L-Arginine Nitric Oxide Pathway in Hypertension. J. Hypertension 1993, 11:639-645.
58. Ho Y.S., Xiong Y., Ma W., Spector A., Ho D.S. Mice lacking catalase develop normally but show differential sensitivity to oxidant tissue injury. J. Biol. Chem. 2004, 279:32804-32812.
59. Hoekstra K.A., Godin D.V., Cheng K.M. Protective role of heme oxygenase in the blood vessel wall during atherogenesis. Biochem. Cell. Biol. 2004, 82:351-359.
60. Hogan M., Cerami A., Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J. Clin. Invest. 1992, 90:1110-1115.
61. Hong H.-J., Hsiao G., Cheng T.-H., Yen M.-H. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 2001, 38:1044-1048.
62. Honing M.L., Morrison P.J., Banga J.D., Stroes E.S., Rabelink T.J. Nitric oxide availability in diabetes mellitus. Diabetes Metab. Rev. 1998, 14:241-249.
63. Horke S., Witte I., Wilgenbus P., Kruger M., Strand D., Forstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007, 115:2055-2064.
64. Hornig B., Landmesser U., Kohler C., Ahlersmann D., Spiekermann S., Christoph A., Tatge H., Drexler H. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001, 103:799-805.
65. Ignarro L.J., Harbison R.G., Wood K.S., Kadowitz P.J. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J. Pharmacol. Exp. Ther. 1986, 237:893-900.
66. Iida S., Chu Y., Weiss R.M., Kang Y.M., Faraci F.M., Heistad D.D. Vascular effects of a common gene variant of extracellular superoxide dismutase in heart failure. Am. J. Physiol. Heart. Circ. Physiol. 2006, 291:H914-H920.
67. Imaizumi T., Hirooka Y., Masaki H., Harada S., Momohara M., Tagawa T., Takeshita A. Effects of L-arginine on forearm vessels and responses to acetylcholine. Hypertension 1992, 20:511-517.
68. Jiang F., Roberts S.J., Datla S., Dusting G.J. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 2006, 48:950-957.
69. Johnson F.K., Johnson R.A., Peyton K.J., Durante W. Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R1057-R1062.
70. Jung O., Marklund S.L., Xia N., Busse R., Brandes R.P. Inactivation of extracellular superoxide dismutase contributes to the development of high-volume hypertension. Arterioscler. Thromb. Vasc. Biol. 2007, 27:470-477.
71. Kerr S., Brosnan M.J., McIntyre M., Reid J.L., Dominiczak A.F., Hamilton C.A. Superoxide anion production is increased in a model of genetic hypertension : role of the endothelium. Hypertension 1999, 33:1353-1358.
72. Klatt P., Pfeiffer S., List B.M., Lehner D., Glatter O., Bachinger H.P., Werner E.R., Schmidt K., Mayer B. Characterization of heme-deficient neuronal nitric-oxide synthase reveals a role for heme in subunit dimerization and binding of the amino acid substrate and tetrahydrobiopterin. J. Biol. Chem. 1996, 271:7336-7342.
73. Klingbeil A.U., John S., Schneider M.P., Jacobi J., Handrock R., Schmieder R.E. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am. J. Hypertens. 2003, 16:123-128.
74. Kotsonis P., Frohlich L.G., Shutenko Z.V., Horejsi R., Pfleiderer W., Schmidt H.H. Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. Biochem. J. 2000, 346(Pt 3):767-776.
75. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U S A 1991, 88:4651-4655.
76. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 2000, 6:1004-1010.
77. Kuzkaya N., Weissmann N., Harrison D.G., Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J. Biol. Chem. 2003, 278:22546-22554.
78. Landmesser U., Bahlmann F., Mueller M., Spiekermann S., Kirchhoff N., Schulz S., Manes C., Fischer D., de Groot K., Fliser D., Fauler G., Marz W., Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356-2363.
79. Landmesser U., Cai H., Dikalov S., McCann L., Hwang J., Jo H., Holland S.M., Harrison D.G. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40:511-515.
80. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., Mitch W.E., Harrison D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003, 111:1201-1209.
81. Landmesser U., Merten R., Spiekermann S., Buttner K., Drexler H., Hornig B. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2000, 101:2264-2270.
82. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 1998, 273:24266-24271.
83. Laursen J.B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B.A., Tarpey M., Fukai T., Harrison D.G. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103:1282-1288.
84. Leus F.R., Zwart M., Kastelein J.J., Voorbij H.A. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 2001, 154:641-649.
85. Li H., Forstermann U. Structure-activity relationship of staurosporine analogs in regulating expression of endothelial nitric-oxide synthase gene. Mol. Pharmacol. 2000, 57:427-435.
86. Li H., Hergert S.M., Schafer S.C., Brausch I., Yao Y., Huang Q., Mang C., Lehr H.A., Forstermann U. Midostaurin upregulates eNOS gene expression and preserves eNOS function in the microcirculation of the mouse. Nitric. Oxide. 2005, 12:231-236.
87. Li H., Junk P., Huwiler A., Burkhardt C., Wallerath T., Pfeilschifter J., Forstermann U. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation 2002, 106:2250-2256.
88. Li H., Oehrlein S.A., Wallerath T., Ihrig-Biedert I., Wohlfart P., Ulshöfer T., Jessen T., Herget T., Förstermann U., Kleinert H. Activation of protein kinase C alpha and/or epsilon enhances transcription of the human endothelial nitric oxide synthase gene. Mol. Pharmacol. 1998, 53:630-637.
89. Li H., Raman C.S., Glaser C.B., Blasko E., Young T.A., Parkinson J.F., Whitlow M., Poulos T.L. Crystal structures of zinc-free and -bound heme domain of human inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitric-oxide synthase. J Biol Chem. 1999, 274:21276-21284.
90. Li H., Witte K., August M., Brausch I., Godtel-Armbrust U., Habermeier A., Closs E.I., Oelze M., Munzel T., Förstermann U. Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol 2006, 47:2536-2544.
91. Li H., Witte K., August M., Brausch I., Gödtel-Armbrust U., Habermeier A., Closs E.I., Oelze M., Münzel T., Förstermann U. Reversal of eNOS uncoupling and upregulation of eNOS expression lowers blood pressure in hypertensive rats. J. Am. Coll. Cardiol. 2006, 47:2536-2544.
92. Liao J.K. Beyond lipid lowering: the role of statins in vascular protection. Int. J. Cardiol. 2002, 86:5-18.
93. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., Tsuji H., Reaven G.M., Cooke J.P. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002, 106:987-992.
94. Lin M.I., Fulton D., Babbitt R., Fleming I., Busse R., Pritchard K.A., Sessa W.C. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J. Biol. Chem. 2003, 278:44719-44726.
95. List B.M., Klosch B., Volker C., Gorren A.C., Sessa W.C., Werner E.R., Kukovetz W.R., Schmidt K., Mayer B. Characterization of bovine endothelial nitric oxide synthase as a homodimer with down-regulated uncoupled NADPH oxidase activity: tetrahydrobiopterin binding kinetics and role of haem in dimerization. Biochem. J. 1997, 323(Pt 1):159-165.
96. Lonn E., Bosch J., Yusuf S., Sheridan P., Pogue J., Arnold J.M., Ross C., Arnold A., Sleight P., Probstfield J., Dagenais G.R. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005, 293:1338-1347.
97. Martasek P., Miller R.T., Liu Q., Roman L.J., Salerno J.C., Migita C.T., Raman C.S., Gross S.S., Ikeda-Saito M., Masters B.S. The C331A mutant of neuronal nitric-oxide synthase is defective in arginine binding. J. Biol. Chem. 1998, 273:34799-34805.
98. Masters B.S., McMillan K., Sheta E.A., Nishimura J.S., Roman L.J., Martasek P. Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO. as a cellular signal. FASEB J. 1996, 10:552-558.
99. Matsuno K., Yamada H., Iwata K., Jin D., Katsuyama M., Matsuki M., Takai S., Yamanishi K., Miyazaki M., Matsubara H., Yabe-Nishimura C. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005, 112:2677-2685.
100. McMillan K., Adler M., Auld D.S., Baldwin J.J., Blasko E., Browne L.J., Chelsky D., Davey D., Dolle R.E., Eagen K.A., Erickson S., Feldman R.I., Glaser C.B., Mallari C., Morrissey M.M., Ohlmeyer M.H., Pan G., Parkinson J.F., Phillips G.B., Polokoff M.A., Sigal N.H., Vergona R., Whitlow M., Young T.A., Devlin J.J. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl. Acad. Sci. U. S. A 2000, 97:1506-1511.
101. McNally J.S., Davis M.E., Giddens D.P., Saha A., Hwang J., Dikalov S., Jo H., Harrison D.G. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H2290-H2297.
102. Miller R.T., Martasek P., Raman C.S., Masters B.S. Zinc content of Escherichia coli-expressed constitutive isoforms of nitric-oxide synthase. Enzymatic activity and effect of pterin. J Biol Chem. 1999, 274:14537-14540.
103. Miller R.T., Martasek P., Roman L.J., Nishimura J.S., Masters B.S. Involvement of the reductase domain of neuronal nitric oxide synthase in superoxide anion production. Biochemistry 1997, 36:15277-15284.
104. Milstien S., Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem. Biophys. Res. Commun. 1999, 263:681-684.
105. Ming X.F., Barandier C., Viswambharan H., Kwak B.R., Mach F., Mazzolai L., Hayoz D., Ruffieux J., Rusconi S., Montani J.P., Yang Z. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 2004, 110:3708-3714.
106. Moat S.J., Clarke Z.L., Madhavan A.K., Lewis M.J., Lang D. Folic acid reverses endothelial dysfunction induced by inhibition of tetrahydrobiopterin biosynthesis. Eur. J. Pharmacol. 2006, 530:250-258.
107. Mollnau H., Wendt M., Szocs K., Lassegue B., Schulz E., Oelze M., Li H., Bodenschatz M., August M., Kleschyov A.L., Tsilimingas N., Walter U., Forstermann U., Meinertz T., Griendling K., Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 2002, 90:E58-E65.
108. Morita T. Heme oxygenase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1786-1795.
109. Mueller C.F., Laude K., McNally J.S., Harrison D.G. Redox mechanisms in blood vessels. Arterioscler. Thromb. Vasc. Biol. 2005, 25:274-278.
110. Münzel T., Li H., Mollnau H., Hink U., Matheis E., Hartmann M., Oelze M., Skatchkov M., Warnholtz A., Duncker L., Meinertz T., Förstermann U. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ. Res. 2000, 86:E7-E12.
111. Nakaki T., Nakayama M., Kato R. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur. J. Pharmacol. 1990, 189:347-353.
112. Ng C.J., Bourquard N., Grijalva V., Hama S., Shih D.M., Navab M., Fogelman A.M., Lusis A.J., Young S., Reddy S.T. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J. Biol. Chem. 2006, 281:29491-29500.
113. Nickenig G., Harrison D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002, 105:393-396.
114. Nickenig G., Baumer A.T., Temur Y., Kebben D., Jockenhovel F., Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100:2131-2134.
115. Noble M.A., Munro A.W., Rivers S.L., Robledo L., Daff S.N., Yellowlees L.J., Shimizu T., Sagami I., Guillemette J.G., Chapman S.K. Potentiometric analysis of the flavin cofactors of neuronal nitric oxide synthase. Biochemistry 1999, 38:16413-16418.
116. Nunokawa Y., Tanaka S. Interferon-gamma inhibits proliferation of rat vascular smooth muscle cells by nitric oxide generation. Biochem. Biophys. Res. Commun. 1992, 188:409-415.
117. O'Driscoll J.G., Green D.J., Rankin J.M., Taylor R.R. Nitric oxide-dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects. Clin. Exp. Pharmacol. Physiol. 1999, 26:779-783.
118. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 1993, 91:2546-2551.
119. Ohashi M., Runge M.S., Faraci F.M., Heistad D.D. MnSOD deficiency increases endothelial dysfunction in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2331-2336.
120. Ohishi M., Ueda M., Rakugi H., Naruko T., Kojima A., Okamura A., Higaki J., Ogihara T. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J. Hypertens. 1997, 15:1295-1302.
121. Paolini M., Sapone A., Canistro D., Chieco P., Valgimigli L. Antioxidant vitamins for prevention of cardiovascular disease. Lancet 2003, 362:920. author reply 921.
122. Pieper G.M. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J. Cardiovasc. Pharmacol. 1997, 29:8-15.
123. Pollock J.S., Forstermann U., Mitchell J.A., Warner T.D., Schmidt H.H., Nakane M., Murad F. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc. Natl. Acad. Sci. U. S. A 1991, 88:10480-10484.
124. Pou S., Pou W.S., Bredt D.S., Snyder S.H., Rosen G.M. Generation of superoxide by purified brain nitric oxide synthase. J. Biol. Chem. 1992, 267:24173-24176.
125. Pritchard K.A., Groszek L., Smalley D.M., Sessa W.C., Wu M., Villalon P., Wolin M.S., Stemerman M.B. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res. 1995, 77:510-518.
126. Radomski M.W., Palmer R.M., Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 1987, 92:639-646.
127. Ramachandran A., Levonen A.L., Brookes P.S., Ceaser E., Shiva S., Barone M.C., Darley-Usmar V. Mitochondria, nitric oxide, and cardiovascular dysfunction. Free Radic. Biol. Med. 2002, 33:1465-1474.
128. Raman C.S., Li H., Martasek P., Kral V., Masters B.S., Poulos T.L. Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell 1998, 95:939-950.
129. Rapoport R.M., Draznin M.B., Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 1983, 306:174-176.
130. Rosenkranz-Weiss P., Sessa W.C., Milstien S., Kaufman S., Watson C.A., Pober J.S. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. J Clin Invest. 1994, 93:2236-2243.
131. Rossitch E., Alexander E., Black P.M., Cooke J.P. L-arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J. Clin. Invest. 1991, 87:1295-1299.
132. Rozenberg O., Shih D.M., Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005, 181:9-18.
133. Schächinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906.
134. Shinozaki K., Kashiwagi A., Nishio Y., Okamura T., Yoshida Y., Masada M., Toda N., Kikkawa R. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. Diabetes 1999, 48:2437-2445.
135. Shinozaki K., Nishio Y., Okamura T., Yoshida Y., Maegawa H., Kojima H., Masada M., Toda N., Kikkawa R., Kashiwagi A. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ. Res. 2000, 87:566-573.
136. Simon A., Plies L., Habermeier A., Martine U., Reining M., Closs E.I. Role of neutral amino acid transport and protein breakdown for substrate supply of nitric oxide synthase in human endothelial cells. Circ. Res. 2003, 93:813-820.
137. Sorescu D., Weiss D., Lassegue B., Clempus R.E., Szocs K., Sorescu G.P., Valppu L., Quinn M.T., Lambeth J.D., Vega J.D., Taylor W.R., Griendling K.K. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002, 105:1429-1435.
138. Southgate K., Newby A.C. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 1990, 82:113-123.
139. Stanner S.A., Hughes J., Kelly C.N., Buttriss J. A review of the epidemiological evidence for the 'antioxidant hypothesis'. Public Health Nutr. 2004, 7:407-422.
140. Stocker R., Perrella M.A. Heme oxygenase-1: a novel drug target for atherosclerotic diseases?. Circulation 2006, 114:2178-2189.
141. Stroes E., Kastelein J., Cosentino F., Erkelens W., Wever R., Koomans H., Luscher T., Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest. 1997, 99:41-46.
142. Stroes E.S., van Faassen E.E., Yo M., Martasek P., Boer P., Govers R., Rabelink T.J. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ. Res. 2000, 86:1129-1134.
143. Stuehr D., Pou S., Rosen G.M. Oxygen reduction by nitric-oxide synthases. J. Biol. Chem. 2001, 276:14533-14536.
144. Sydow K., Munzel T. ADMA and oxidative stress. Atheroscler. Suppl. 2003, 4:41-51.
145. Taille C., El-Benna J., Lanone S., Dang M.C., Ogier-Denis E., Aubier M., Boczkowski J. Induction of heme oxygenase-1 inhibits NAD(P)H oxidase activity by down-regulating cytochrome b558 expression via the reduction of heme availability. J. Biol. Chem. 2004, 279:28681-28688.
146. Torzewski M., Ochsenhirt V., Kleschyov A.L., Oelze M., Daiber A., Li H., Rossmann H., Tsimikas S., Reifenberg K., Cheng F., Lehr H.A., Blankenberg S., Forstermann U., Munzel T., Lackner K.J. Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:850-857.
147. Touyz R.M., Yao G., Schiffrin E.L. c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23:981-987.
148. Turrens J.F., Alexandre A., Lehninger A.L. Ubisemiquinone is the electron donor for superoxide formation by complex III of heart mitochondria. Arch. Biochem. Biophys. 1985, 237:408-414.
149. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., Lusis A.J., Shih D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
150. van Etten R.W., de Koning E.J., Verhaar M.C., Gaillard C.A., Rabelink T.J. Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 2002, 45:1004-1010.
151. Vaziri N.D., Ni Z., Oveisi F. Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension 1998, 31:1248-1254.
152. Vergnani L., Hatrik S., Ricci F., Passaro A., Manzoli N., Zuliani G., Brovkovych V., Fellin R., Malinski T. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation 2000, 101:1261-1266.
153. Verhaar M.C., Stroes E., Rabelink T.J. Folates and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2002, 22:6-13.
154. Verhaar M.C., Wever R.M., Kastelein J.J., van Dam T., Koomans H.A., Rabelink T.J. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998, 97:237-241.
155. Vita J.A., Treasure C.B., Nabel E.G., McLenachan J.M., Fish R.D., Yeung A.C., Vekshtein V.I., Selwyn A.P., Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990, 81:491-497.
156. Wagner A.H., Kohler T., Ruckschloss U., Just I., Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 2000, 20:61-69.
157. Warnholtz A., Nickenig G., Schulz E., Macharzina R., Brasen J.H., Skatchkov M., Heitzer T., Stasch J.P., Griendling K.K., Harrison D.G., Bohm M., Meinertz T., Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999, 99:2027-2033.
158. Wassmann S., Laufs U., Baumer A.T., Muller K., Ahlbory K., Linz W., Itter G., Rosen R., Bohm M., Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001, 37:1450-1457.
159. Wassmann S., Laufs U., Baumer A.T., Muller K., Konkol C., Sauer H., Bohm M., Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001, 59:646-654.
160. Werner E.R., Gorren A.C., Heller R., Werner-Felmayer G., Mayer B. Tetrahydrobiopterin and nitric oxide: mechanistic and pharmacological aspects. Exp. Biol. Med. 2003, 228:1291-1302.
161. Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G., Schmidt K., Weiss G., Wachter H. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J. Biol. Chem. 1993, 268:1842-1846.
162. White C.R., Brock T.A., Chang L.Y., Crapo J., Briscoe P., Ku D., Bradley W.A., Gianturco S.H., Gore J., Freeman B.A., Tarpey M.M. Superoxide and peroxynitrite in atherosclerosis. Proc. Natl. Acad. Sci. U. S. A 1994, 91:1044-1048.
163. White C.R., Darley-Usmar V., Berrington W.R., McAdams M., Gore J.Z., Thompson J.A., Parks D.A., Tarpey M.M., Freeman B.A. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc. Natl. Acad. Sci. U. S. A 1996, 93:8745-8749.
164. Whitsett J., Martasek P., Zhao H., Schauer D.W., Hatakeyama K., Kalyanaraman B., Vasquez-Vivar J. Endothelial cell superoxide anion radical generation is not dependent on endothelial nitric oxide synthase-serine 1179 phosphorylation and endothelial nitric oxide synthase dimer/monomer distribution. Free Radic. Biol. Med. 2006, 40:2056-2068.
165. Wilmink H.W., Stroes E.S., Erkelens W.D., Gerritsen W.B., Wever R., Banga J.D., Rabelink T.J. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 2000, 20:185-188.
166. Woo K.S., Chook P., Lolin Y.I., Sanderson J.E., Metreweli C., Celermajer D.S. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J. Am. Coll. Cardiol. 1999, 34:2002-2006.
167. 2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J. Biol. Chem. 1998, 273:25804-25808.
168. Xu W., Kaneko F.T., Zheng S., Comhair S.A., Janocha A.J., Goggans T., Thunnissen F.B., Farver C., Hazen S.L., Jennings C., Dweik R.A., Arroliga A.C., Erzurum S.C. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 2004, 18:1746-1748.
169. Yamashiro S., Kuniyoshi Y., Arakaki K., Miyagi K., Koja K. The effect of insufficiency of tetrahydrobiopterin on endothelial function and vasoactivity. Jpn. J. Thorac. Cardiovasc. Surg. 2002, 50:472-477.
170. Yamawaki H., Haendeler J., Berk B.C. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ. Res. 2003, 93:1029-1033.
171. Yang H., Roberts L.J., Shi M.J., Zhou L.C., Ballard B.R., Richardson A., Guo Z.M. Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E. Circ. Res. 2004, 95:1075-1081.
172. Yoshida K., Okamura T., Kimura H., Bredt D.S., Snyder S.H., Toda N. Nitric Oxide Synthase-Immunoreactive Nerve Fibers in Dog Cerebral and Peripheral Arteries. Brain Res. 1993, 629:67-72.
173. Yoshida T., Maulik N., Engelman R.M., Ho Y.S., Magnenat J.L., Rousou J.A., Flack J.E., Deaton D., Das D.K. Glutathione peroxidase knockout mice are susceptible to myocardial ischemia reperfusion injury. Circulation 1997, 96:II-216-II-220.
174. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. J. Med. 2000, 342:145-153.
175. Zalba G., San Jose G., Moreno M.U., Fortuno M.A., Fortuno A., Beaumont F.J., Diez J. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001, 38:1395-1399.
176. Zhang C., Hein T.W., Wang W., Chang C.I., Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J. 2001, 15:1264-1266.
177. Zhang C., Hein T.W., Wang W., Miller M.W., Fossum T.W., McDonald M.M., Humphrey J.D., Kuo L. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004, 44:935-943.
178. 2. Hypertension 2005, 46:732-737.